

Editor-in-Chief

Prof. Dr. Diane M. Harper
University of Missouri-Kansas City, USA
E-Mail: diane.m.harper@gmail.com

Editorial Board

- Pedro L. Alonso (Spain)
- Jay A. Berzofsky (USA)
- Joseph E. Blaney, Jr. (USA)
- Thierry Boon (Belgium)
- Olga Borges (Portugal)
- Sandra S. Chaves (USA)
- Genoveffa Franchini (USA)
- Eli Gilboa (USA)
- Marc P. Girard (France)
- Elena A. Govorkova (USA)
- Guido Grandi (Italy)
- Chinnaswamy Jagannath (USA)
- Aisha O. Jumaan (USA)
- Matti Osmo Antero Lehtinen (Finland)
- Sven-Eric Olsson (Sweden)
- Mark Pearson (Australia)
- Barbara Romanowski (Canada)
- K. Rose (USA)
- Daniel A. Salmon (USA)
- Pramod K. Srivastava (USA)
- Stanley S. Tai (USA)
- Sjoerd H. van der Burg (The Netherlands)
- Zhou Xing (Canada)

Facts about the MDPI Community

70 open access journals
70 staff at your disposal
4000 academic editors
15,000 articles published
26,000 e-mail alert subscribers
60,000 unique authors
150,000 academic peer-reviewers
600,000 monthly PDF views
2,400,000 monthly abstract views

MDPI AG
Postfach
CH-4005 Basel
Switzerland

Tel. +41 61 683 7734
Fax +41 61 302 8918

Vaccines is an independent open access
journal published by MDPI

www.mdpi.com

(Please visit: www.mdpi.com/journal/vaccines/editors/
for an updated version, January 2012)

See www.mdpi.com/about/contact/ for a full list of offices and contact
information. MDPI AG is a company registered in Basel, Switzerland,
No. CH-270.3.014.334-3, whose registered office is at Kanderer-
strasse 25, CH-4057 Basel, Switzerland.

vaccines

Call for Papers



Call for Papers

Dear Colleagues,

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Vaccines* (ISSN 2076-393X). *Vaccines* is an international, peer-reviewed, open access journal (free for readers) focused on laboratory and clinical vaccine research, utilization and immunization.

Manuscripts prepared in Microsoft Word or LaTeX can be submitted to the Editorial Office online at www.mdpi.com. Detailed instructions for authors are also available online: www.mdpi.com/journal/vaccines/instructions/

Vaccines is published in open access format—research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public can unlimitedly access the content for free as soon as it is published.

Vaccines is a new journal and publication fees are fully waived for papers submitted in 2012. However, a fee of 250 CHF may apply for those articles that need major editing and formatting and/or English editing.

We would be pleased to welcome you as one of our authors.

Vaccines Editorial Office
E-Mail: vaccines@mdpi.com
Tel. +41 61 683 7734
www.mdpi.com/journal/vaccines/

Aims & Scope

Vaccines publishes high quality reviews, regular research papers, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in open access form in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

There are, in addition, unique features of this journal: Manuscripts regarding research proposals and research ideas will be particularly welcomed; Computed data or files regarding the full details of the experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material; We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds.

Subject Areas:

- immunology mechanisms
- animal models for immunologic diseases
- viral immunology
- immunopathogenesis
- vaccine development and efficacy evaluation
- immune responses to vaccines
- vaccine technology
- vaccine vectors, adjuvants and immunomodulators
- prophylactic vaccines, therapeutic vaccines, AIDS vaccines, gene vaccines, vaccines in bioterrorism
- regulatory affairs, commercial utilization, policy, safety, epidemiology

Vaccines regularly publishes special issues on relevant and timely topics. Be sure to check our website for an updated list of special issues: www.mdpi.com/journal/vaccines/

Open Access. What Does it Really Mean?

Open access is mainly a response to what is known as the serials crisis: yearly increasing journal subscription prices, which make subscription-based journals increasingly difficult to afford.

Many university libraries around the world have had to cancel existing subscriptions, or are unable to keep up with subscribing to new journals, because the cost of publication has risen disproportionately to their budgets.

With open access publishing, the cost of peer-review and production of an article is borne by the institute of the author by payment of a onetime flat fee. Conversely, readers and their institutes are no longer charged for accessing the journals they need.

For researchers, open access brings the convenience of immediate access to the literature that they need—no matter for which university or company they work, or whether they just want to read a paper in their spare time at home.

For authors, open access means a much wider circle of readers due to the easy access to their research papers. The interested general public is also able to access research works, giving higher transparency to the outcome of taxpayer money spent on research.